Study Description

A multicenter, randomized, double-blind, phase II, safety and efficacy study of xxx vs. placebo in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy.

Length of study: up to11 weeks

Number of office visits: up to 8 visits

Qualified participants will receive either investigational study medication or placebo added to standard antidepressant. Participants will receive study related care at no cost and will be compensated for time and travel.

Study inclusion/exclusion criteria

This study is enrolling individuals who:

• Read and understand English
• Meet criteria for Major Depressive Disorder
• Are 18 to 65 years old
• Has a current inadequate response to an antidepressant
• Are without serious health problems
• Do not have certain conditions such as Bipolar Disorder, Obsessive-Compulsive Disorder, or Schizophrenia
• Do not have a recent drug or alcohol abuse history
• Are not cannabis users

Contact us at:

California Neuroscience Research Medical Group, Inc.
4835 Van Nuys Blvd., Suite 104
Sherman Oaks, CA 91403
(818) 990-2671
lilit@cnrmg.com
 

[Home] [For Patients] [Studies] [FAQ] [Sponsor Overview] [Contact Us]